Acorda's new Parkinson's disease drug shows improved results

CVT-301 showed significant improvement in motor functions during a Phase 3 clinical trial. | File photo

Acorda Therapeutics' CVT-301, a drug used in treating people with Parkinson’s disease, showed significant improvement in motor functions during a Phase 3 clinical trial.

“We are greatly encourage by the efficacy and safety results of this trial, which validate the positive reults,” Acorda Chief Medical Officer Burkhar Blank said in a press release. “We would like to express our gratitude to the study volunteers and clinical investigators who participated in this trial to advance our understanding of this potentially important therapy for people with Parkinson’s.”

Want to get notified whenever we write about Acorda Therapeutics, Inc. ?
Next time we write about Acorda Therapeutics, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Acorda Therapeutics, Inc. 420 Saw Mill River Rd Ardsley, NY 10502